List view / Grid view
Drug Target Review’s Ria Kakkad recently visited ELRIG and the British Pharmacological Society’s conference on New Modalities in Pharmacology and Drug Discovery which took place in London, UK. This article shares some of the key takeaways from the event.
Scientists have created a new imaging technique with graphene which generates clearer pictures of the structures of small molecules.
NRG is developing a pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with potential as first-in-class treatments for Parkinson's disease and motor neuron disease.
Using chemical genetic screening and pre-clinical model studies, researchers have discovered that inducing ubiquitin-mediated degradation of mutant EZH2 could provide a more effective treatment strategy for haematologic malignancies.
The length of time that drug molecules attach to their target protein varies greatly and impacts the protein’s behaviour and drug efficacy. In a new study, scientists in Finland have identified some causal factors for this variance, with the hope it will bring clarity for drug developers.
Sanofi and Exscientia will develop up to 15 novel drug candidates by leveraging the latter's AI discovery and optimisation platform.
In this latest episode, we discuss how small molecule discovery can be automated and how this process saves researchers time and money.
The new study identified PDZ-binding kinase (PBK) as a promising target for pulmonary hypertension and assessed two PBK inhibitors.
The new nanotechnology left six of 10 mice with lymphoma tumour-free and was effective in melanoma when combined with existing drugs.
Researchers developed a platform that can rapidly screen thousands of compounds to identify potential antiviral drugs to treat coronaviruses.
The study reveals the biological mechanism that causes nerve destruction in amyotrophic lateral sclerosis (ALS), potentially leading to treatments that reverse the disease.
A new study provides an in-depth review on the designs and applications of morphology-transformable nanoparticles to improve cancer therapies.
Scientists identified three prototypical RNA-expression states and revealed differences in their susceptibility to a variety of cancer drugs.
The new research shows how interleukin-17a (IL-17a) can alter the trajectory of immune system development and cause gut inflammation.
Scientists have found that SARS-CoV-2 can knock out an important molecular pathway linked to an immune complex called MHC class I.
